Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a very successful treatment option for both TYpe 2 Diabetes and obesity […]

Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, as it affects nearly 70% of patients with diabetes. Thus far […]

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14313 There is more evidence accumulating that semaglutide, the GLP-1 medication originally approved for diabetes, and subsequently for weight reduction, protects against […]

A just published study from JAMA Open Network that examined the health records of people with type 2 diabetes and opioid […]

The European Medicines Agency’s Committee for Medicinal Products is recommending an update to Novo Nordisk’s medication Wegovy’s (semaglutide 2.4 mg) […]

Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP1-RA) approved for type 2 diabetes mellitus (Ozempic) and obesity (Wegovy). 1 […]

A study just published in JAMA Internal Medicine https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080 showed that a greater weight loss occurred for study subjects who used Tirzepatide (Mounjaro or […]

A new study released by the makers of the weight loss medication Wegovy (Semaglutide) finds that it reduced the occurrence of kidney problems by […]

WEIGHT LOSS MEDICATIONS REDUCE COLON CANCER RISK Newly completed research published in the scientific journal JAMA Oncology (Journal of the […]

ZEPBOUND : THE NEW WEIGHT LOSS MEDICATION The FDA has just published a news release regarding its approval of Zepbound […]